



# Investor Presentation


May 2023

# Forward Looking Statements

This presentation has been prepared by Movano Inc. ("we," "us," "our," "Movano" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

# The intersection of consumer wearables & medical devices is a \$50B opportunity in the US alone




# Investment Opportunity

---

- › Innovative solutions at the intersection of consumer and medical device
- › Developed proprietary Radio Frequency (RF) chip to drive blood pressure and glucose features in future products
- › Capital efficient and disciplined operating culture

Launching first  
consumer  
wearable device,  
the Evie Ring,  
September 2023





CES  
announce  
coverage  
signals a  
major  
opportunity  
for a female  
focused  
wearable



Evie ring  
press  
generated  
over 5B  
impressions  
across 50+  
outlets

## The Evie Ring may have a grip on women's wellness other wearables don't




### The awesome new Evie smart ring beats Oura in one major way



By Kate Kozuch published 1 day ago

Evie could shake up the smart ring market

Comments (2)



## 11 "BEST OF CES" AWARDS



PHANDROID

billboard



Reviewed

WIRED

YD  
YANKO DESIGN

# North American FemTech market

**\$48B by 2030<sup>1</sup>**



Women make up more than half of the U.S. population, and control or influence 85% of consumer spending<sup>2</sup>



Nearly half of US women earn the same, or more, as their partner<sup>3</sup>

# Women are more likely to be dismissed or misdiagnosed by the healthcare system



While more connected to the healthcare system, most feel dismissed by providers.<sup>1</sup>



Heart disease is the #1 cause of death for women in the U.S.<sup>2</sup>



92% of women feel unprepared for menopause<sup>3</sup>



"Menopause symptoms" Google searches have doubled since 2019<sup>4</sup>



# We asked 1000 women to tell us about their personal health journey...



## THIS IS WHAT THEY SAID:

Three-quarters are in the **wearable/tracking market**, with a third currently tracking via a watch or fitness tracker.


She is looking for a **trusted resource to help her find more energy** for her day, **strength** to engage with family and stay on top of daily tasks.

She **wants a more holistic overview of her health**, beyond a moment in time; no compulsive exercise or counting calories.

› Women between the ages of 35 and 75 in a series of 20 min interviews

› Currently own or looking to purchase a wearable  
› Nationally representative sample who live in the U.S.

# How Evie is different




Uniquely designed for women



First medical grade consumer wearable


App delivers meaningful & actionable insights





Accessible price point at \$269 with no subscription




# Meet Evie



# Strong lead gen growth with minimal investment indicates healthy consumer demand



More than 80,000 signups



Nearly 500,000 visitors to [eviering.com](https://eviering.com)



Evie digital campaigns have served over **24M** impressions since January

# Importance of Medical Device



# We are a medical device company



## Differentiated Infrastructure



Quality Management System & QRC Team

FDA-Compliant Contract Manufacturer

Clinical Lab for IRB-Approved Studies



## Operating at a Higher Standard



Design Control & Risk Management Procedures


HIPAA-Compliant Systems

# Expect to file for FDA clearance on SpO<sub>2</sub> & HR data in June 2023


## Q4 Hypoxia Pivotal Trial Results

	SpO <sub>2</sub> RMSE <sup>1</sup>	HR RMSE <sup>2</sup>
FDA Benchmark	<3.5%	Within 2 bpm
Masimo - Radical-7	2.8%	1.5 bpm
Evie Ring	2.13%	~ 2 bpm

SpO<sub>2</sub>



Heart Rate







# Movano Health Solutions Value Proposition



## Device Sales

- › Robust and Consumer-Tested User Experience



## Data Services

- › Processed Real-Time Data and Population-Level Insights



**Help Accelerate Drug or Device Development, Demonstrate Treatment Efficacy, Real-Time Data Access**

# An FDA-cleared ring would address unique needs for strategic partners



## Med device companies

- › FDA-cleared wearables to enhance in-house solutions



## Pharmaceutical companies

- › Medical-grade data for clinical trial and post-market surveillance



## Healthcare networks

- › Improving remote care through visibility into daily health metrics



## Payors

- › FDA cleared tool for improving member health and reversing cost curve

# Beta tests with world-class partners

## Beta 1 Partners



Global pharmaceutical company

Leading patient-focused medical device company

## Beta 2 Partners

Two global medical device companies

Global athletic apparel company

# Blood Pressure and Glucose

# Our patented System-on-a-Chip was built from the ground up

After four years in development, the smallest ever custom RF-enabled IC designed for blood pressure and glucose monitoring is now functional, providing:


Greater accuracy

Flexibility in form factor

Cost-effective solutions

## THE POWER OF 4 CHIPS IN 1

Meet Movano Health's custom mmWave integrated sensor





# Movano Health patent summary

US: 21 Issued, 32 Pending

PCT International applications  
pending: 1

Foreign: 1 Issued (China), 3  
pending (1 China/2 Europe)



## Our US patents fall into three families:

### RF IC Architecture

(3) Issued

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

#### Key Issued Patents:

- › Systems for multi-band radar-based sensing (US 11,298,037)
- › Methods for multi-band radar-based sensing (US 10,874,314)

### RF-Based Health Monitoring

(15) Issued  
(25) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level, techniques for alignment of RF sensor, techniques related to optical/RF sensor fusion.

#### Key Issued Patents:

- › Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)
- › Systems for RF-based health monitoring generating alignment signals (US 11,206,993)
- › Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)
- › Systems for health monitoring using radio waves that include collocated RF components (US 11,464,418)
- › Systems for health monitoring using radio waves that include mixing signals at different frequencies (US 11,583,199)
- › Methods for radio wave based health monitoring that utilize data derived from amplitude and/or phase data (US 11,576,586)-

### Machine Learning Applications

(2) Issued  
(8) Pending

Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

#### Key Issued Patents:

- › Methods for training a model for use in RF-based health monitoring (US 11,464,419)
- › Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)

# Corporate Snapshot

# Our seasoned team has expertise across critical domains

## Medtech

**John Mastrototaro, PhD**

**CEO | DIRECTOR**

Former Medtronic/MiniMed exec.  
30 years medical device industry

**Kim Tompkins**

**VP | QRC**

30+ years FDA Class II/III devices,  
digital health & cardiovascular

**Nan Kirsten Forte**

**DIRECTOR**

Digital health pioneer & innovator,  
Exec VP and GM Everyday Health  
& Former Exec VP WebMD

## Technology

**Michael Leabman**

**CTO | FOUNDER**

CTO of 4 wireless startups  
20+ years smart antenna  
experience  
200+ issued patents

**Ed Landau**

**VP | ENGINEERING**

25+ years in product development  
in medical & consumer tech  
electronics

**Rubén Caballero**

**DIRECTOR**

Microsoft VP Engineering,  
Formerly Apple VP Engineering

## Finance

**J. Cogan, CFA**

**CFO**

24 years Wall Street experience,  
investor & analyst

**Emily Fairbairn**

**CHAIR OF THE BOARD**

Co-founder Ascend Capital  
30+ years Wall Street experience

**Brian Cullinan**

**DIRECTOR**

2x Lead Director PwC US Board  
30+ years PwC Partner

## Go to Market

**Tyla Bucher**

**CMO**

20+ years building & launching  
global integrated brand  
campaigns for consumer products  
and media companies

**Stacy Salvi, JD**

**VP | STRATEGY**

Former Head of Strategic  
Partnerships for Fitbit at Google

**Michael Soule**

**VP | BUSINESS DEVELOPMENT**

20+ years managing sales,  
strategy & business development  
for consumer product and medical  
device companies

# Corporate Snapshot (Nasdaq : MOVE)

**Year founded:**  
2018

**Dollars raised:**  
\$93M

**IP portfolio:**  
US 21 patents issued, 32 pending  
OUS 1 patent issued (China), 4 patents pending

**LTM cash burn 3/31/23:**  
\$25M

**Number of FTEs:**  
36

**Cash at 3/31/23 :**  
\$14.3M

**Corporate entities:**  
Movano Inc. dba  
Movano Health

Movano Ireland  
Limited

# Conclusion



Developing solutions at the intersection of medical and consumer devices.



\$50B D2C & B2B TAM opportunity, given our focus on medical grade data.



The Evie smart ring, the first wearable designed uniquely for women is a foundational product, launching September 2023 for \$269 with no subscription.



Proprietary RF technology is the engine that drives blood pressure and glucose initiatives.



Significant progress alongside capital efficiency – operating culture focused on both customers and shareholders.





# NASDAQ: MOVE

---

+1 (415) 651-3172

6800 Koll Center Pkwy.  
Pleasanton, CA 94566

[www.movanohealth.com](http://www.movanohealth.com)

